STAT3 and urinary bladder carcinoma: Several scientists have demonstrated that when STAT3‐specific siRNA knock‐downs STAT3 expression or inhibitor (ie Stattic) inhibits STAT3 activity, it decreases the IC50 of THP treatment dramatically in bladder cancer cells.7 This indicates that STAT3 plays an important role in the pharmacodynamics of THP.